Research Article Summary
• Primary focus:
This article proposes the use of half-body low-dose irradiation (LDI) as a potential adjuvant therapy for patients with resected exocrine pancreatic cancer. Traditional adjuvant therapy after surgery — typically chemotherapy or chemoradiation — improves median survival modestly, but overall prognosis remains poor due to high rates of recurrence. The authors suggest exploring LDI as a novel adjunctive approach. Hilaris Publishing SRL
• Rationale for LDI:
Unlike conventional high-dose radiation therapy (e.g., 200 cGy per fraction to the tumor site), half-body LDI uses very low doses (around 10–15 cGy per fraction) delivered to a large portion of the body. The goal is not direct tumor killing, but rather stimulation of the body’s adaptive protection systems, including immune function and repair mechanisms, which may help eliminate micrometastatic disease that survives surgery. Hilaris Publishing SRL
• Treatment strategy:
The proposed protocol involves starting LDI soon after surgery, potentially before conventional adjuvant chemotherapy begins. The rationale is that LDI may enhance wound healing and stimulate systemic defense mechanisms without delaying standard therapy. Doses are repeated over weeks, and the authors hypothesize that a booster series may prolong the protective effect for months or years. Hilaris Publishing SRL
• Comparison with conventional therapy:
Conventional adjuvant therapies are known to prolong median survival in resected pancreatic cancer (e.g., from 15 to 28 months), but outcomes are still poor due to persistent microscopic disease. LDI therapy is proposed as a way to improve on these outcomes by engaging broad systemic responses, while minimizing side effects because of its low dose and non-destructive approach. Hilaris Publishing SRL
• Potential benefits and monitoring:
The authors suggest that LDI could be well tolerated with little symptomatic toxicity. Effectiveness might be monitored using serum tumor markers such as CA 19-9 during and after treatment. If insufficient response is observed, conventional therapy could still be applied without significant delay. Hilaris Publishing SRL
Please click here to read the full research article:
https://www.researchgate.net/publication/338447607_Adjuvant_Therapy_for_Resected_Exocrine_Pancreatic_Cancer_by_Half-Body_Low-Dose_Irradiation ← original research article